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SUMMARY
We conducted prospective, community-wide surveillance for acute respiratory illnesses (ARIs) in
Rochester, NY and Marshfield, WI during a 3-month period in winter 2011. We estimated the
incidence of ARIs in each community, tested for viruses, and determined the proportion of ARIs
associated with healthcare visits. We used a rolling cross-sectional design to sample participants,
conducted telephone interviews to assess ARI symptoms (defined as a current illness with feverishness
or cough within the past 7 days), collected nasal/throat swabs to identify viruses, and extracted
healthcare utilization from outpatient/inpatient records. Of 6492 individuals, 321 reported an ARI
within 7 days (4·9% total, 5·7% in Rochester, 4·4% in Marshfield); swabs were collected from 208
subjects. The cumulative ARI incidence for the entire 3-month period was 52% in Rochester [95%
confidence interval (CI) 42–63] and 35% in Marshfield (95% CI 28–42). A specific virus was identified
in 39% of specimens: human coronavirus (13% of samples), rhinovirus (12%), RSV (7%), influenza
virus (4%), human metapneumovirus (4%), and adenovirus (1%). Only 39/200 (20%) had a healthcare
visit (2/9 individuals with influenza). ARI incidence was ∼5% per week during winter.
Key words: Acute respiratory illnesses (ARIs), influenza, respiratory syncytial virus (RSV).
INTRODUCTION
Seasonal influenza disease causes substantial morbid-
ity in the United States – 200 000 annual hospitaliza-
tions, thousands of annual deaths [1], and many
emergency department (ED) and outpatient visits
[2–4]. Most recent studies of the burden of influenza
disease have focused on healthcare visits; few have
examined the community-wide burden of influenza
in the general population [5, 6]. Because many indivi-
duals with influenza disease do not seek medical care
but are nevertheless ill enough to miss work or school
[7–12], the high morbidity documented in studies of
influenza-related illness may underestimate the burden
of influenza. With vaccination coverage hovering at
only 50% (43% in the 2010–2011 season, http://www.
cdc.gov/flu/fluvaxview/coverage_1011estimates.htm) [13]
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despite universal vaccination recommendations [14], it
is important to understand the full impact of this virus
at the population level.
Other viruses also cause acute respiratory illnesses
(ARIs) and it is important to document their
population-wide impact. A Healthy People 2020 goal
is to prevent disease, disability, and death from infec-
tious disease. Population-level surveillance is an inte-
gral step in assessing morbidity from ARIs. Also
vaccines are in development for several viral pathogens
including respiratory syncytial virus (RSV) [15],
parainfluenza viruses (PIVs) [16], and human metap-
neumovirus (hMPV, first identified in the early 2000s)
which are significant causes of hospitalizations,
ED visits and outpatient visits [2, 17–19]. Longitudinal
community-based surveillance studies conducted in the
1960s–1980s found that RSV and PIVs accounted for
many ARIs [6, 20–24] yet few recent studies have
assessed their population-wide burden and little is
known about the incidence of hMPV in the general
population. Finally, while rhinoviruses (RVs) [25], cor-
onaviruses (CoVs) [26], and other viruses [2] are known
to cause medically attended ARI-related visits, studies
on their population-wide burden are lacking. Such
knowledge could guide future vaccine development.
We conducted a prospective, population-wide sur-
veillance study in two distinct geographical areas to
assess the incidence of ARIs during the winter
months. Our objectives were to (1) estimate, at the
population level, the incidence of ARIs across the
age spectrum; (2) identify the common viruses cur-
rently causing ARIs throughout the community and
their relative frequency; (3) compare the types of
viruses causing ARIs in child vs. adult populations;
and (4) estimate the proportion of individuals in the
community with ARIs who make a healthcare visit.
MATERIAL AND METHODS
The study was approved by institutional review boards
at the University of Rochester and Marshfield Clinic
Research Foundation.
Study design
Our prospective, population-wide surveillance study
used a previously described rolling cross-sectional
(RCS) study design [27] in two communities
(Rochester, NY and Marshfield, WI) in the 2011 win-
ter season to identify individuals with ARIs (defined
as a current illness with feverishness or cough within
the past 7 days) and document viruses associated
with these ARIs. The RCS design was first described
and used by political scientists in the early 1980s for
studies of voter preferences and election results; it con-
sists of a series of cross-sectional samples in which
each sample is representative of the source population
[28]. A random sample of subjects was selected each
week and then interviewed by telephone to identify
those with ARIs and to obtain demographic and
disease-specific information. Consenting individuals
provided nasal and throat swabs which were tested
in a research laboratory by real-time polymerase
chain reaction (rPCR) for a wide spectrum of viruses.
Study setting and sampling frame
We performed the study in two communities labelled
‘Rochester’ and ‘Marshfield’: (a) Monroe County,
NY surrounding the city of Rochester (population
∼744 000); and (b) the Marshfield, Wisconsin area
(population ∼49 000). The Rochester sampling frame
comprised 12 primary-care practices (six internal medi-
cine, four paediatric, one family medicine, and one
medicine-paediatrics practice) serving 90 245 patients
whose age, race/ethnicity, and health insurancemirrored
the demographics of Monroe County. These practices
were from the Greater Rochester Practice-based
Research Network [29]. The Marshfield sampling
frame consisted of 49 000 residents of the Marshfield
Epidemiologic StudyArea (MESA), a population-based
cohort of residents living in 14 zip codes surrounding
Marshfield; >90% of MESA resident receive their
healthcare at Marshfield Clinic [30].
Subject identification
The study focused on individuals (not households).
Participants were identified at random from the two
source populations. In Rochester, we created a de-
nominator of all eligible individuals by merging the
practice-level patient databases across 12 practices.
We used random digit-dialling to call the primary con-
tact telephone number (mobile or land-line) and called
490–825 people/week (based on previous power calcula-
tions), enrolling 118–247 subjects/week. In Marshfield,
we randomly called 500–800 individuals/week and en-
rolled 250–400 subjects/week. In both communities, a
person was eligible if he/she was aged 56 months as
of 1 January, had at least one healthcare encounter in
the previous 24 months, and was a resident of Monroe
County (Rochester) or a member of MESA
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(Marshfield) for 512 continuous months prior to 1
January or since birth for those aged <1 year.
Rochester subjects received a letter from their primary-
care physician explaining the study and that an inter-
viewer would telephone them for consent to participate.
Surveillance timelines
Using protocols developed by the CDC-funded New
Vaccine Surveillance Network [2] and Influenza Vac-
cine Effectiveness (VE) Network [31], the two sites
initiated telephone calls when the University laborator-
ies (Rochester) or the Marshfield Laboratories and
Wisconsin State Laboratory of Hygiene identified52
positive influenza specimens within 1 week or one posi-
tive specimen/week for 2 consecutive weeks, and
stopped calls when laboratories failed to meet this
threshold. The surveillance periods were 11 January
2011 to 1 April 2011 (Rochester) and 17 January 2011
to 8 April 2011 (Marshfield), identical to surveillance
in a parallel studyof influenza vaccine effectiveness [31].
Telephone interview process
We used trained telephone interviewers to perform
structured interviews. From the randomly selected
list of individuals to call each week, interviewers called
6 days/week (Monday–Saturday, Rochester) or 7
days/week (Marshfield) during daytime and evening
hours. On Monday–Friday in both communities,
study enrollers were given a list of new patients to
call and attempted to contact individuals on their
assigned day for verbal consent and an interview.
Up to three calls (morning, afternoon, early evening)
were made per day to telephone numbers listed on
practice patient lists. If contact was unsuccessful on
the assigned day, interviewers continued calls for 2
days, up to three calls per day, with times staggered.
Individuals from the source population could be eli-
gible more than once in subsequent weeks (96% of
those who agreed to participate were enrolled once).
Content of telephone interviews
Telephone interviewers screened subjects for ARI
symptoms in the identified person (subject or child)
over the past 7 days, described the study, and obtained
verbal consent for a survey that included a symptom
assessment. Subjects with ARI symptoms in the past
7 days were defined as ARI positive; the remainder
were defined as ARI negative.
In Rochester, if the sampled person was a child
aged 417 years, the interviewer spoke with a parent
or guardian. The interviewer conducted a brief
computer-assisted interview to determine if the subject
had new onset of feverishness or cough within 7 days.
Telephone procedures in Marshfield were the same
except: parents were interviewed if subjects were aged
412 years; subjects aged 13–18 years were inter-
viewed but with parental consent.
If a potential subject with an ARI was identified,
the telephone interviewer obtained the date of symp-
tom onset and specific symptoms experienced (using
a checklist of symptoms), and asked for verbal consent
for an in-person visit to conduct an interview and col-
lect nasal/throat specimens for viral testing; they were
compensated $20 for a home visit or $30 for a clinic
visit (or community site). Subjects with no ARI symp-
toms were compensated with a $5 gift card.
In-person interviews and specimen collection
In-person visits were conducted within 7 days of the
onset of illness symptoms to (1) obtain written consent
for specimens and access to subjects’ medical records
for ARI-related information, (2) complete a brief
interview to gather additional health-related informa-
tion (ARI symptoms 47 days, and in Rochester –
sites for medical care for the ARI), and (3) obtain
nasal/throat swabs for testing for viruses. Research
staff met subjects at their home or a convenient loca-
tion in Rochester or at clinics in Marshfield. Enrollers
collected one nasal and one throat swab for testing.
Medical chart (electronic medical record) reviews
Trained abstractors reviewed medical records of
ARI-positive cases for: (1) ARI-related healthcare vis-
its (primary care, speciailty, ED, urgent care, or hos-
pitalization) occurring within 7 days before or after
the interview; (2) procedures obtained during visits
(chest radiograph, bloodwork, nasopharyngeal or re-
spiratory cultures, rapid antigen testing); and (3) pri-
mary diagnosis for outpatient and ED visits and all
diagnoses for hospitalizations.
Laboratory procedures
Nasal/throat specimens were combined in transport
media, processed and stored at −80 °C. Laboratory
testing was performed at the University of
Rochester. Total nucleic acid was extracted according
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to the manufacturer’s protocol using the QIAamp
Viral RNA Mini kit on a QIAcube robotic instrument
(Qiagen, USA). Specimens were tested by TaqMan
Array Card (TAC) methodology (Life Technologies,
USA), which allows simultaneous, singleplex, rPCR
to be performed in a 384-well microfluidic card format
[32]. We tested specimens for influenza virues A and
B, RSV, PIV1–4, RV, adenovirus, hMVP, and CoVs
229E, NL63, OC43 and HKU1 by TAC assay. All pri-
mer and probe oligonucleotide sequences used for PCR
assays were prepared and optimized by CDC. TAC
assays demonstrated high sensitivity (75–95%) for
influenza, RSV, PIV2–4, RV, and hMPV, and moder-
ate sensitivity (54–56%) for PIV1 and adenovirus com-
pared with individual-virus PCRs [33]. The four CoV
rPCR assays were highly sensitive and specific for the
detection of CoV 229E, NL63, OC43 and HKU1,
with positive predictive values in the TAC assay of
94%, 97%, 96% and 88%, respectively [34].
Statistical analyses
We assessed the frequency of each virus and also mul-
tiple viruses and tabulated results for all subjects, by
age [child (6 months–18·9 years) vs. adult], setting
(Rochester vs. Marshfield), and whether subjects had
sought medical care for ARIs. We used tabular ana-
lyses to summarize diagnoses/procedures for subjects
with ARI-related medical visits. We used Pearson’s
χ2 tests to compare individual viruses between adult
and child ARI positive subjects. In instances where
expected values were 1–5 we corrected the χ2 test stat-
istic with the N – 1 correction, and used Fisher’s exact
test when expected cell sizes were <1 [35]. We esti-
mated population-wide ARI and individual virus cu-
mulative incidence during the 3-month study period
by summing the percent of the population that had a
newARI (symptoms for47 days) eachweek (i.e. week-
ly incidence). For instance, if we had run a 3-weekRCS,
and weekly incidences were 2%, 3% and 4%, we would
calculate the cumulative incidence as 9%.
We used a stratified biased corrected and acceler-
ated bootstrap procedure to calculate 95% confidence
intervals (CIs) for population-wide proportions, with
1000 replications [36].
RESULTS
Incidence of ARIs during the influenza season (Fig. 1)
In Rochester, 17 485 telephone calls were made, 4130
calls were completed (i.e. direct contact with a
household member), 2683 (65%) agreed to participate
in symptom assessment and were enrolled, of whom
2263 (84%) consented for medical chart review for
influenza vaccination dates. Altogether, 98 nasal/
throat specimens were collected (64% of ARI sub-
jects); one specimen was invalid with no ribonucleo-
protein (RNP) human cellular control detected. Of
individuals contacted by telephone, 153 had an ARI
with feverishness or cough for a weekly (i.e. ARI with-
in the previous 6 days) mean ARI incidence of 5·7%.
The cumulative incidence for ARI during the
3-month study period was 52% (95% CI 42–63) as
shown in Figure 2. It was 21% when restricted to sub-
jects for whom a viral respiratory pathogen was
detected (95% CI 15–28).
In Marshfield, 20 530 telephone calls were made,
5538 calls were completed, 3809 (69%) subjects agreed
to participate, 3261 (86%) consented for a medical
chart review. Altogether 115 nasal/throat specimens
were collected (69% of ARI subjects); five specimens
were invalid with no RNP human cellular control
detected. Of individuals contacted by telephone, 167
had an ARI for a weekly mean ARI incidence of
4·4%. The cumulative ARI incidence during the
3-month study period was 35% (95% CI 28–42) as
shown in Figure 2; it was 14% when restricted to virus-
positive ARIs (95% CI 10–19).
Across both sites and all ages, 43·1% of individuals
had an ARI during the 3-month study period (78·5%
of children, 33·7% of adults). In Rochester, none of
the subjects qualified on the basis of fever alone. In
Marshfield, five of the 46 children aged <19 years
and one of the 69 adults qualified on the basis of
fever alone.
The gender distribution of ARI cases was slightly dif-
ferent than the source population (e.g. in Rochester 42%
of ARI cases were female, vs. 44% from the source; in
Marshfield 61% were female vs. 51%). ARI cases were
slightly older (e.g. in Rochester 75% of ARI cases were
adults aged >19 years, vs. 70% from the source popula-
tion; in Marshfield 60% of ARI cases were adults vs.
77% from the source).
Viruses associated with ARIs during the influenza
season (Table 1)
In 61% of ARI cases, no viruses were identified, in
35% a single virus was identified, and in 4% of cases
2–3 viruses were identified. The most common viruses
were CoVs (14% of all ARI cases), followed by RVs
(12%), RSV (7%), influenza viruses (4%), hMPV
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(4%), and adenovirus (1%). The distribution of viruses
varied – subjects from Marshfield experienced more
ARIs from CoVs and those from Rochester had
more from RVs.
Types of viruses associated with ARIs in children vs.
adults (Table 2)
Influenza viruses were identified in 1% of ARIs in chil-
dren and 7% in adults. RSV was identified in a greater
proportion of ARIs in children, while CoVs and RVs
were identified in a high proportion of ARIs in both
children and adults. At least one virus was identified
in 45% of ARIs in children and 37% in adults; two
viruses were identified in 8% of children with ARIs
and 2% of adults.
Healthcare utilization in individuals with ARIs
(Table 3)
Out of the 200 subjects with ARIs and who also
agreed to a medical record review (seven from
Rochester did not agree), 39 (19%) had a healthcare
visit, five (2·5%) had an ED visit, and three (1·5%)
had a hospitalization, all within 7 days of illness
onset. Of the 39 with a healthcare visit, 30 (79%)
were to primary care.
Of 84 participating children with ARIs, healthcare
utilization data were available from medical charts
for 79 children, and 20 (25%) had a healthcare visit.
Of 123 adults with ARIs, healthcare utilization was
available for 118 adults; 19 (16%) had a healthcare
visit.
Given the small number of specific viral infections
detected, it was not possible to compare healthcare
utilization patterns by virus. The single child with an
influenza infection did have a healthcare visit; 1/8
adults with influenza had a healthcare visit.
DISCUSSION
This RCS study is one of the few recent epidemio-
logical studies to assess the incidence and causes of
ARIs in the general population. We performed the
study during the respiratory season (January to early
April), when influenza detections were occurring
weekly. Our study has several important findings.
First, the overall incidence of ARI with feverishness
or cough per week was 4·9% (ranging from 4·4% in
Marshfield to 5·7% in Rochester), for a cumulative
Rochester Marshfield
Eligible population
N=90 245
Eligible population
N~49 000
Completed telephone calls
N=4 130
Agreed to participate
N=2 683 (65%)
ARI in past 7 days
N=153 (5.7% of agred)
ARI specimen collected
N=98 (64% of ARIs)
Valid ARI specimen
N=97 (99% of ARI specimens)
Completed telephone calls
N=5 538
Agreed to participate
N=3 809 (69%)
ARI in past 7 days
N=167 (4.4% of agreed)
ARI specimen collected
N=115 (69% of ARIs)
Valid ARI specimen
N=110 (97% of ARI specimens)
Not called
(or reached)
Did not
agree
No ARI
No
specimen
collected
Invalid
ARI
specimen
Telephone
calls
Consent
Screening
for ARI
ARI
specimen
collection
Fig. 1. Flow chart for numbers of individuals contacted, with acute respiratory illnesses (ARIs), and number of ARI
specimens.
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incidence during a 3-month respiratory season of 52%
in Rochester and 35% in Marshfield. Second, despite
use of advanced molecular techniques, we were able
to identify viruses from only 39% of individuals with
ARI symptoms. Third, influenza viruses accounted
for only 11% of virus-positive cases, or 4% of all
ARI cases. Fourth, the distribution of viruses was
similar for children vs. adults. Finally, only one-fifth
of ARI cases (and 2/9 influenza cases) had a health-
care visit for the ARI.
Several groundbreaking longitudinal cohort studies
of respiratory illnesses were conducted from 1948 to
1976: the Cleveland Family Study, the Houston
Family Study, the New York Virus Watch, the
Tecumseh Study, and the Seattle Virus Watch [5, 10,
22–24, 37]. In these early studies, overall annual
ARI incidence rates per person-year ranged from 4·5
to 8·0 for children aged <5 years of age and from
1·3 to 6·2 for individuals aged 55 years. Because of
differences in ARI symptom criteria, our focus on
Fig. 2. Number of acute respiratory illness (ARI) cases by week of surveillance, by geographical site. (a) Rochester, (b)
Marshfield.
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wintertime incidence only, and differences in study
designs, findings from our study cannot be directly
compared with many of these classic studies.
However, we estimated that one-third of adults and
nearly four-fifths of children in our two communities
developed 51 ARI during the 3-month respiratory
period. A recent household cohort study from
Michigan [38] found that the mean number of ARIs
per individual over a 6-month period that coincided
with our 3-month period was 1·1 for children aged
<5 years and 0·6 for adults aged 18–49 years – these
results are similar to ours, despite the differences in
study design. Further studies over multiple years
would be helpful to better understand the current pat-
terns of ARI incidence in the community setting.
The weekly (or by extrapolation, 3-month) incidence
of ARIs reported by our subjects in two US commun-
ities was in the range of the incidence of ARIs reported
in a telephone survey of residents of Australia during
the 2008–2009 season, reported in this journal [39].
In that telephone-based survey, 20% of subjects self-
reported ARI symptoms (based on very similar de-
finitions to ours) within the past 4 weeks. Our study
extends findings from the Australian study by identify-
ing viruses associated with ARIs and healthcare utili-
zation patterns of individuals with ARIs.
We found that during the ‘flu season’ of 2010–2011,
influenza caused only 1% of ARIs in children and 7%
in adults. These findings contrast with early longitu-
dinal studies [5, 10, 22–24, 37] and the recent
Michigan cohort study [38] in which influenza
accounted for a higher proportion of ARIs. Data
from previously published New Vaccine Surveillance
Network studies (which included the Rochester site)
found that during peak influenza season, influenza-
related ARIs accounted for up to one-quarter of ED
visits in children aged <5 years [3].
Table 1. Viruses associated with acute respiratory
illnesses
Rochester
(n= 97)*
Marshfield
(n= 110)*
Total
(N= 207)*
Influenza 5 (5%) 4 (4%) 9 (4%)
Influenza A 4 4 8
Influenza B 1 0 1
Respiratory syncytial
virus
7 (7%) 7 (6%) 14 (7%)
Parainfluenza (PIV) 1 (1%) 3 (3%) 4 (2%)
PIV-1 0 0 0
PIV-2 0 0 0
PIV-3 1 3 4
PIV-4 0 0 0
Rhinovirus 17 (18%) 8 (7%) 25 (12%)
Human coronavirus
(HCV)
8 (8%) 20 (18%) 28 (14%)
HCV-1 (229E) 0 0 0
HCV-2 (NL63) 2 9 11
HCV-3 (OC43) 5 6 11
HCV-4 (HKU1) 1 5 6
Adenovirus 1 (1%) 1 (1%) 2 (1%)
Human
metapneumovirus
5 (5%) 4 (4%) 9 (4%)
At least 1 virus
identified
38 (39%) 43 (39%) 81 (39%)
1 virus identified 33 (34%) 39 (35%) 72 (35%)
52 viruses identified 5 (5%) 4 (4%) 9 (4%)
No viruses identified 59 (61%) 67 (61%) 126 (61%)
The sum of the virus-specific percentages and the percen-
tages of ‘no virus identified’ range between 104% and
106% because more than one virus present in some subjects.
* Valid acute respiratory illness specimens.
Table 2. Distribution of viruses for children versus
adults
Children
(n= 84)
Adults
(n= 123) P value
Influenza 1 (1) 8 (7) 0·06*
Respiratory syncytial virus 9 (11) 5 (4) 0·06
Parainfluenza 3 (4) 1 (1) 0·16*
Rhinovirus 14 (17) 11 (9) 0·09
Human coronavirus 11 (13) 17 (14) 0·88
Adenovirus 2 (2) 0 (0) 0·16†
Human metapneumovirus 5 (6) 4 (3) 0·35*
At least 1 virus identified 38 (45) 43 (36) 0·14
No viruses identified 46 (55) 80 (64) 0·14
52 viruses identified 7 (8) 2 (2) 0·02*
P values from the Pearson χ2 test.
* Uses the N – 1 χ2 test.
†Uses Fisher’s exact test.
Table 3. Healthcare utilization in subjects with ARIs
Rochester
(n= 90)
Marshfield
(n= 110)
Total
(N = 200)
Did not have any
healthcare visits
71 (79%) 90 (82%) 161 (81%)
Had a healthcare visit
for the ARI*
19 (21%) 20 (18%) 39 (20%)
Primary care office 14 (78%) 16 (80%) 30 (79%)
ED or urgent care 4 (22%) 1 (5%) 5 (13%)
Hospitalization 0 3 (15%) 3 (8%)
ARI, Acute respiratory illness; ED, emergency department.
* Based on medical chart reviews, ARI-related healthcare
visit within 7 days prior to the telephone interview and 7
days post-interview.
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The low rates of influenza detection in subjects with
ARI in our community-based study were likely
influenced by several factors. Across the United
States, the 2010–2011 influenza season was less severe
than the 2009–2010 pandemic year or the 2007–2008
seasonal influenza season, but more severe than the
2008–2009 influenza season, with overall hospitaliza-
tion rates around 19–20/100 000 individuals of all
ages [40]. Further, despite suboptimal influenza vac-
cination rates, influenza vaccination may have low-
ered the relative disease burden from this virus,
although the tremendous variability in the timing, in-
tensity, and duration of influenza circulation from
year-to-year makes such assessments difficult.
Vaccination rates were 59% and 41% in the
Rochester and Marshfield study populations, respect-
ively, and it was estimated that vaccine effectiveness in
preventing medically attended influenza visits in a
four-community study that included both Rochester
and Marshfield was 60% during the same influenza
season as assessed in our study [31]. Moreover, while
our criteria for definition of ARIs comprised a list of
symptoms used by other studies of medically attended
ARI-related visits, these criteria may have been too
broad and some patients labelled with ARI in this
study may not have had a respiratory virus. For ex-
ample, we included feverishness as one ARI criteria.
Our data highlight several additional aspects of the
current epidemiology of ARI. While we confirm the
high prevalence of RV, RSV, and PIV as aetiological
agents of ARI, we also documented high rates of
ARIs associated with CoVs and hMPV, a finding
also highlighted by the recent Michigan cohort study
[38]. Our previous studies of medically attended ARI
visits have noted that these two viruses are associated
with ARI-related medical visits [19, 26]. Together,
these findings highlight the potential value of future
vaccines against these two viruses.
We noted that the pattern of viruses was generally
similar for children and adults, although there was a
trend toward a greater proportion of ARIs being at-
tributable to RSV in children than in adults. These
mirror findings from cohort studies [5, 10, 22–24,
37, 38].
We found that only one-fifth of ARI cases had a
healthcare visit, and that four-fifths of these medical
visits were to a primary-care physician. A similar pat-
tern was noted in both children and adults, and in
both communities. Our study strongly suggests that
the burden of ARIs is vastly greater than the burden
demonstrated by studies limited to ARI-associated
healthcare visits. Thus, efforts to develop vaccines to
reduce ARIs have the potential for substantial
benefit in reducing the disease burden from
community-based ARIs as well as reducing medically
attended healthcare visits. Future studies should con-
sider collecting additional data on the morbidity of
ARIs that do not result in visits to healthcare
providers.
Our study has several strengths, including rigorous-
ly defined protocols across both communities, large
numbers of individuals contacted by random sam-
pling, trained staff to obtain nasal/throat specimens
and conduct chart reviews, case definitions that mir-
rored the definitions used in studies of medically
attended ARIs, and detection of viral infections by
advanced molecular techniques. However, we caution
against over-interpretation of our findings due to sev-
eral important limitations. First, we studied only two
communities, during a single respiratory season over a
3-month period which missed the peak season for PIV
and RV. Geographical and seasonal variability in the
viral aetiologies of ARI are substantial [2, 7, 10], for
example, it is difficult to draw inferences about ARI
incidence or virus burden from a single season of sur-
veillance. Also, the relative contribution of some
viruses might be different had we included a longer
study period. Second, while our strict definition of
ARIs (current illness with feverishness or cough) likely
excluded other causes of stuffiness such as allergies, we
may have missed some ARIs. Third, we interviewed
only two-thirds of persons contacted, and obtained
nasal/throat specimens for only two-thirds of ARI
cases. We are aware of some selection bias in subjects
agreeing to be interviewed. For example, Rochester
subjects who agreed were more likely than the original
sampling frame to be male and adult. While others
have noted lower ARI reports in men [41], our ARI
findings do not vary by gender; also we stratify
findings by age group. It is possible that subjects
from whom specimens were collected differed by
viral aetiology or other characteristics. Fourth, despite
making >38 000 telephone calls, we were able to col-
lect only 208 nasal/throat swabs from subject with
ARIs. Our sample sizes for individual viruses are
small. Fifth, we may have missed some subjects who
would have tested positive for a viral respiratory
pathogen because we performed nasal swabs and
used TAC detection methods rather than nasopharyn-
geal swabs and more sensitive conventional PCR
assays. Sixth, we selected subjects with symptoms for
47 days, but it is possible that some were no longer
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shedding virus, especially if they underestimated their
days of symptoms prior to being contacted. Finally,
we simply summed estimated weekly ARI incidence
to derive a cumulative incidence, using a RCS design.
This method has not yet been validated against more
standard methods to calculate cumulative incidence in
traditional cohort studies.
CONCLUSION
We conclude that in the 2011 winter respiratory sea-
son, about one in 20 individuals within two communi-
ties had an ARI during any single week, and one-third
to one-half had an ARI during the winter respiratory
season. Of those with ARIs, influenza infection
accounted for only 4% of cases, while RSV, PIV, RV,
CoV, and hMPV accounted for the bulk of ARIs. In
individuals with ARIs, four-fifths did not make a visit
to a healthcare provider because of their symptoms.
ARIs due to both influenza and other viruses cause sub-
stantialmorbidity undetected by the healthcaredelivery
system. In an era when actively following large cohorts
of consenting subjects for disease surveillance purposes
is expensive and resource intensive, the use of RCS
designs similar to ours may offer a reasonable alterna-
tive strategy for conducting surveillance for more com-
mon illnesses. New vaccines for several common
respiratory viruses may hold promise for further redu-
cing the population-wide disease burden from ARIs.
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